Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Other Non-Current Liabilities (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Other Non-Current Liabilities data on record, last reported at $10.1 million in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 21.45% year-over-year to $10.1 million; the TTM value through Dec 2025 reached $10.1 million, up 21.45%, while the annual FY2025 figure was $10.1 million, 21.45% up from the prior year.
  • Other Non-Current Liabilities reached $10.1 million in Q4 2025 per TLSI's latest filing, up from $5.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $22.6 million in Q1 2024 and bottomed at $369000.0 in Q4 2022.
  • Average Other Non-Current Liabilities over 4 years is $9.6 million, with a median of $8.2 million recorded in 2025.
  • Peak YoY movement for Other Non-Current Liabilities: skyrocketed 4949.32% in 2023, then tumbled 63.75% in 2025.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $369000.0 in 2022, then surged by 4949.32% to $18.6 million in 2023, then crashed by 55.37% to $8.3 million in 2024, then rose by 21.45% to $10.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $10.1 million in Q4 2025, $5.0 million in Q3 2025, and $7.5 million in Q2 2025.